Drug Search Results
More Filters [+]

Vorolanib

Alternative Names: vorolanib, cm-082, cm082, cm 082, x82, x-82, x 82
Latest Update: 2024-10-31
Latest Update Note: News Article

Product Description

ÊVorolanib (CM082) is a multi-target tyrosine kinase inhibitor including VEGF, PDGF, c-kit, and Flt-3. (Sourced from: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.10040)

Mechanisms of Action: VEGFR Inhibitor,PGFR Inhibitor,CSF-1R Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AnewPharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vorolanib

Countries in Clinic: China, United States, Unknown Location

Active Clinical Trial Count: 8

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Thoracic Cancer|Thymoma|Wet Macular Degeneration

Phase 1: Acute Myeloid Leukemia|Gastrointestinal Cancer|Healthy Volunteers|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

VICC THO 1802

P2

Completed

Thoracic Cancer|Thymoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

2024-02-21

CTR20182458

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

2020-01-16

CTR20160487

P1

Not yet recruiting

Acute Myeloid Leukemia

None

CTR20201168

P1

Not yet recruiting

Healthy Volunteers|Oncology Solid Tumor Unspecified

None

Recent News Events